Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Wegovy helps Novo Nordisk beats forecasts, but sales growth tipped to slow

(Sharecast News) - Novo Nordisk reported better-than-expected fourth quarter profit on the back of surging demand for its Wegovy weight loss drug but also said 2025 sales growth would slow slightly as competition for obesity treatments intensified. Net profit at the Danish drug giant was up 29% to 28.23 billion Danish kroner (£3.14bn), compared with estimates of DKK 26.09BN. For the full year profit rose 21% to DKK 100.99bn, just above forecasts of DKK 99.14BN.

Sales of Wegovy, more than doubled to DKK 19.87bn in the final three months of 2024, slightly missing the DKK 20.02bn forecast by analysts.

The company forecast slower sales growth for this year of 16% - 24% on a constant exchange rate basis, below forecasts of 18% - 26%, with Novo Nordisk citing "intensifying competition and continued pricing pressure within Diabetes and Obesity care".

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.